A Phase 2b dose-evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
This study is currently recruiting participants.
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give Pazopanib eye drops to adults with Wet AMD compared to Ranibizumab injections.
Ages Eligible for Study: 50 years old and older
Genders Eligible for Study: Both
Dr. Richard Rosen, Retina Vitreous Specialist
Katy Tai, Research Manager
firstname.lastname@example.org or 212-979-4251